Fidelity Investments
XERS icon

Fidelity Investments’s Xeris Biopharma Holdings XERS Stock Holding History

Fidelity Investments’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.1M Buy
644,057
+130,981
+26% +$836K ﹤0.01% 2400
2026
Q1 		$2.98M Buy
513,076
+73,371
+17% +$486K ﹤0.01% 2498
2025
Q4 		$3.45M Buy
439,705
+79,527
+22% +$626K ﹤0.01% 2406
2025
Q3 		$2.93M Buy
360,178
+33,758
+10% +$224K ﹤0.01% 2403
2025
Q2 		$1.52M Buy
326,420
+14,948
+5% +$68.5K ﹤0.01% 2579
2025
Q1 		$1.71M Buy
311,472
+263,698
+552% +$1.06M ﹤0.01% 2497
2024
Q4 		$162K Buy
47,774
+26,334
+123% +$84.7K ﹤0.01% 3356
2024
Q3 		$61.1K Buy
21,440
+407
+2% +$1.04K ﹤0.01% 3698
2024
Q2 		$47.3K Buy
21,033
+7,885
+60% +$15.9K ﹤0.01% 3646
2024
Q1 		$29.1K Buy
13,148
+677
+5% +$1.75K ﹤0.01% 3847
2023
Q4 		$29.3K Buy
12,471
+3,179
+34% +$5.87K ﹤0.01% 3758
2023
Q3 		$17.3K Sell
9,292
-52
-0.6% -$119 ﹤0.01% 3880
2023
Q2 		$24.5K Buy
9,344
+232
+3% +$591 ﹤0.01% 3755
2023
Q1 		$14.9K Buy
9,112
+5,897
+183% +$7.38K ﹤0.01% 3972
2022
Q4 		$4.28K Buy
3,215
+284
+10% +$401 ﹤0.01% 4306
2022
Q3 		$5K Buy
2,931
+2,084
+246% +$3.45K ﹤0.01% 4343
2022
Q2 		$1K Buy
847
+344
+68% +$726 ﹤0.01% 4818
2022
Q1 		$1K Buy
+503
New +$1.23K ﹤0.01% 4860
2020
Q2 		– Sell
-266,300
Closed -$519K – 4225
2020
Q1 		$519K Buy
+266,300
New +$1.15M ﹤0.01% 2424
2019
Q4 		– Sell
-4,048,102
Closed -$39.8M – 4317
2019
Q3 		$39.8M Buy
4,048,102
+668,389
+20% +$7.51M ﹤0.01% 1278
2019
Q2 		$38.7M Buy
3,379,713
+416,695
+14% +$4.37M ﹤0.01% 1342
2019
Q1 		$29.7M Buy
2,963,018
+682,050
+30% +$8.74M ﹤0.01% 1424
2018
Q4 		$38.8M Buy
2,280,968
+447,937
+24% +$8.99M 0.01% 1251
2018
Q3 		$32.2M Buy
1,833,031
+1,031,231
+129% +$22.4M ﹤0.01% 1488
2018
Q2 		$15.2M Buy
+801,800
New +$15.6M ﹤0.01% 1813

Other funds holding XERS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Fidelity Investments's XERS Position: Q2 2026 in Review

Fidelity Investments increased its Xeris Biopharma Holdings (XERS) stake by 26% in Q2 2026, buying an estimated $836K and bringing the position to 644,057 shares worth $5.1M. The position accounts for ﹤0.01% of the portfolio, ranked #2400.

Fidelity Investments first reported a position in XERS in Q2 2018 and has held it in 25 quarters since. The position peaked at $39.8M in Q3 2019. 241 funds tracked by Wall St. Rank hold XERS as of Q2 2026.

  • Fidelity Investments held 644,057 shares of Xeris Biopharma Holdings worth $5.1M as of Q2 2026.
  • Fidelity Investments bought 130,981 Xeris Biopharma Holdings shares in Q2 2026, an estimated $836K.
  • Xeris Biopharma Holdings made up ﹤0.01% of Fidelity Investments's portfolio in Q2 2026, its #2400 holding.
  • Fidelity Investments first reported a position in Xeris Biopharma Holdings in Q2 2018 and has held it in 25 quarters since.
  • Fidelity Investments's Xeris Biopharma Holdings position peaked at $39.8M in Q3 2019.
  • 241 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q2 2026.

Based on Fidelity Investments's 13F filing for Q2 2026, filed 13 Aug 2026.